NASDAQ:PTGX - Protagonist Therapeutics Stock Price, Forecast & News

Protagonist Therapeutics trades on the NASDAQ under the ticker symbol "PTGX."

Protagonist Therapeutics Inc (NASDAQ:PTGX) released its earnings results on Wednesday, November, 6th. The company reported ($0.61) EPS for the quarter, topping analysts' consensus estimates of ($0.71) by $0.10. The firm earned $4.14 million during the quarter, compared to analyst estimates of $5.75 million. Protagonist Therapeutics had a negative net margin of 209.02% and a negative return on equity of 74.86%. View Protagonist Therapeutics' Earnings History.

Protagonist Therapeutics is scheduled to release their next quarterly earnings announcement on Tuesday, March 10th 2020. View Earnings Estimates for Protagonist Therapeutics.

5 Wall Street analysts have issued 12 month target prices for Protagonist Therapeutics' shares. Their forecasts range from $17.00 to $29.00. On average, they expect Protagonist Therapeutics' stock price to reach $21.50 in the next twelve months. This suggests a possible upside of 193.7% from the stock's current price. View Analyst Price Targets for Protagonist Therapeutics.

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Protagonist Therapeutics in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Protagonist Therapeutics.

News stories about PTGX stock have trended positive this week, according to InfoTrie. InfoTrie scores the sentiment of news coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Protagonist Therapeutics earned a media sentiment score of 2.2 on InfoTrie's scale. They also assigned media headlines about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the company's share price in the near future. View News Stories for Protagonist Therapeutics.

Protagonist Therapeutics saw a increase in short interest during the month of November. As of November 29th, there was short interest totalling 1,160,000 shares, an increase of 32.5% from the November 14th total of 875,200 shares. Based on an average daily trading volume, of 616,900 shares, the short-interest ratio is presently 1.9 days. Currently, 6.3% of the shares of the company are short sold. View Protagonist Therapeutics' Current Options Chain.

Some companies that are related to Protagonist Therapeutics include CannTrust (CNTTF), Stoke Therapeutics (STOK), Akebia Therapeutics (AKBA), Aprea Therapeutics (APRE), ANI Pharmaceuticals (ANIP), Revance Therapeutics (RVNC), Clovis Oncology (CLVS), Collegium Pharmaceutical (COLL), Kiniksa Pharmaceuticals (KNSA), Axovant Sciences (AXON), Urogen Pharma (URGN), Kura Oncology (KURA), Intra-Cellular Therapies (ITCI), Omeros (OMER) and Cara Therapeutics (CARA).

Based on aggregate information from My MarketBeat watchlists, some companies that other Protagonist Therapeutics investors own include Energy Transfer LP Unit (ET), ImmunoGen (IMGN), Novavax (NVAX), Viking Therapeutics (VKTX), Fate Therapeutics (FATE), Amicus Therapeutics (FOLD), Ocular Therapeutix (OCUL), Strongbridge Biopharma (SBBP), SCYNEXIS (SCYX) and Synergy Pharmaceuticals (SGYP).

(PTGX) raised $70 million in an initial public offering on Thursday, August 11th 2016. The company issued 5,800,000 shares at a price of $11.00-$13.00 per share. Leerink Partners, Barclays and BMO Capital Markets served as the underwriters for the IPO.

Protagonist Therapeutics' stock is owned by a variety of of institutional and retail investors. Top institutional investors include Millennium Management LLC (3.08%), State Street Corp (1.16%), Point72 Asset Management L.P. (0.60%), Squarepoint Ops LLC (0.31%), Russell Investments Group Ltd. (0.29%) and California State Teachers Retirement System (0.10%). Company insiders that own Protagonist Therapeutics stock include Bryan Giraudo, David Y Liu, Dinesh V Ph D Patel, Donald A Kalkofen, Richard S Shames, Suneel Gupta, Thomas P O'neil and X LP Canaan. View Institutional Ownership Trends for Protagonist Therapeutics.

PTGX stock was sold by a variety of institutional investors in the last quarter, including Squarepoint Ops LLC, Barclays PLC and Eqis Capital Management Inc.. Company insiders that have sold Protagonist Therapeutics company stock in the last year include David Y Liu, Dinesh V Ph D Patel and Richard S Shames. View Insider Buying and Selling for Protagonist Therapeutics.

PTGX stock was purchased by a variety of institutional investors in the last quarter, including Millennium Management LLC, Point72 Asset Management L.P., Russell Investments Group Ltd., State Street Corp, Tuttle Tactical Management, Metropolitan Life Insurance Co NY, Meeder Asset Management Inc. and California State Teachers Retirement System. Company insiders that have bought Protagonist Therapeutics stock in the last two years include Bryan Giraudo, Donald A Kalkofen and Suneel Gupta. View Insider Buying and Selling for Protagonist Therapeutics.

Shares of PTGX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of PTGX stock can currently be purchased for approximately $7.32.

Protagonist Therapeutics has a market capitalization of $199.15 million and generates $30.92 million in revenue each year. The company earns $-38,920,000.00 in net income (profit) each year or ($1.74) on an earnings per share basis. Protagonist Therapeutics employs 64 workers across the globe.View Additional Information About Protagonist Therapeutics.

The official website for Protagonist Therapeutics is http://www.protagonist-inc.com/.

Protagonist Therapeutics' mailing address is 7707 GATEWAY BLVD. SUITE 140, NEWARK CA, 94560. The company can be reached via phone at 510-474-0170 or via email at [email protected]